

Disclosure

Dr. Buse is an investigator (I), consultant (C) or both (I/C) without any direct financial benefit to him under contracts between his employer and the following companies, all regarding diabetes and its co-morbidities:

- Amylin Pharmaceutical, Inc. I/C
- Andromeda I
- AstraZeneca C
- Bayhill Therapeutics C
- Biodel C
- Boehringer Ingelheim I/C
- Bristol-Myers Squibb I/C
- Catabasis C
- Cebix* C
- Diartis C
- Elcelyx C
- Eli Lilly and Co. I/C
- Exsulin C
- GI Dynamics C
- Halozyme, Inc. I
- Hoffman-LaRoche Inc. I/C
- Johnson & Johnson I
- Lexicon I
- LipoScience C
- Medtronic MiniMed, Inc. I
- Merck C
- Metabolon C
- Novan C
- Novo Nordisk Pharmaceuticals, Inc. I/C
- Osiris Therapeutics, Inc. C
- Orexigen C
- Pfizer, Inc. I
- Sanofi I
- Tolerex I
- Transition Therapeutics I
- TransPharma C

John Buse, MD, PhD
November 14, 2011

*Contracts with these entities have not been completed but are under negotiation